Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma

Autor: Ralf A. Linker, Michael Platten, Claudia Becker, Katharina Sahm, Peter Hau, Susan S. Jick, Christoph R. Meier, Michael F. Leitzmann, Corinna Seliger, Tareq M. Anssar
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Oncology
Male
Cancer Research
Allergy
610 Medizin
Inflammatory bowel disease
0302 clinical medicine
Risk Factors
glioma
Odds Ratio
Longitudinal Studies
Child
Original Research
ddc:610
Brain Neoplasms
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
030220 oncology & carcinogenesis
Child
Preschool
Female
Cancer Prevention
Immunosuppressive Agents
Adult
medicine.medical_specialty
Adolescent
autoimmune diseases
glioma
immunosuppressive therapies
immunosuppressive therapies
lcsh:RC254-282
03 medical and health sciences
Young Adult
Immune system
Internal medicine
Glioma
Diabetes mellitus
medicine
Humans
Radiology
Nuclear Medicine and imaging
autoimmune diseases
Asthma
Autoimmune disease
business.industry
Infant
Newborn
Infant
Odds ratio
medicine.disease
Inflammatory Bowel Diseases
Survival Analysis
United Kingdom
030104 developmental biology
Logistic Models
Case-Control Studies
business
Zdroj: Cancer Medicine, Vol 9, Iss 3, Pp 1263-1275 (2020)
Cancer Medicine
ISSN: 2045-7634
Popis: Effectors from the immune system can modulate the course and possibly the early development of gliomas. We, therefore, hypothesized that autoimmune diseases associated with increased immune‐surveillance may also modulate the risk of human glioma. To test this hypothesis, we used data from the well‐validated Clinical Practice Research Datalink (CPRD) GOLD from the UK to analyze the association of immune‐related disorders or use of immunosuppressive drugs and the risk of glioma. We identified 3112 incident glioma cases diagnosed between 1995 and 2017. We randomly selected up to 10 controls, matching them to glioma cases on age, sex, index date, general practice, and number of years of active history in the database prior to the index date. We performed conditional logistic regression analyses to estimate Odds Ratios (ORs) of glioma among those exposed to allergies, autoimmune diseases, and immunosuppressive drugs. Overall, we found no materially altered association between a history of any autoimmune disease (OR 0.98, 95% CI 0.86‐1.11), allergy (OR 0.97, 95% CI 0.89‐1.05), or use of immunosuppressive drugs and the risk of glioma. However, subgroup analyses among younger patients found a statistically significant increased risk of glioma in patients with a history of inflammatory bowel disease (IBD) (OR 2.59, 95% CI 1.31‐5.12). There was also an inverse association between asthma and risk of glioma in patients with longer survival (OR 0.73, 95% CI 0.58‐0.91) and between long‐term duration diabetes and risk of glioma (OR 0.71, 95% CI 0.53‐0.96).
The immune system is increasingly recognized as a key player in glioma pathobiology. Small case‐control studies have found inverse associations between autoimmune diseases and glioma incidence. We performed a large case‐control study, which did not replicate these associations. However, our data indicate that inflammatory bowel disease (IBD) among patients ≤40 years are associated with an increased risk of glioma. Further studies are needed to explore the role of IBD and altered microbiota in glioma.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje